Anti-TNF Treatment in Crohn's Disease: Toward Tailored Therapy?

被引：7
作者：
D'Haens, Geert [1 ,2 ]
机构：
[1] Imelda GI Clin Res Ctr, Bonheiden, Belgium
[2] Univ Leuven, Louvain, Belgium
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2010年 / 105卷 / 05期
关键词：
SCHEDULED MAINTENANCE TREATMENT; RANDOMIZED-TRIAL; INFLIXIMAB; ADALIMUMAB; ANTIBODIES;
D O I：
10.1038/ajg.2010.15
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Infliximab is a potent therapy for induction and maintenance of remission in Crohn's disease. Unfortunately, many patients lose response and/or develop allergic reactions caused by the chimeric antibody. By means of measuring the presence of antibodies against infliximab and the trough levels of the drug, it seems easier to predict whether patients will respond to intensified dose regimens or will rather benefit from a switch to alternative agents.
引用
收藏
页码：1140 / 1141
页数：2
相关论文
共 15 条
  • [1] AFIF WA, 2009, AM J GASTROENTEROL, V105
  • [2] Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
    Baert, F
    Noman, M
    Vermeire, S
    Van Assche, G
    D'Haens, G
    Carbonez, A
    Rutgeerts, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) : 601 - 608
  • [3] Adalimumab for the treatment of fistulas in patients with Crohn's disease
    Colombel, J-F
    Schwartz, D. A.
    Sandborn, W. J.
    Kamm, M. A.
    D'Haens, G.
    Rutgeerts, P.
    Enns, R.
    Panaccione, R.
    Schreiber, S.
    Li, J.
    Kent, J. D.
    Lomax, K. G.
    Pollack, P. F.
    [J]. GUT, 2009, 58 (07) : 940 - 948
  • [4] Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
    Colombel, Jean-Frederic
    Sandborn, William J.
    Rutgeerts, Paul
    Enns, Robert
    Hanauer, Stephen B.
    Panaccione, Remo
    Schreiber, Stefan
    Byczkowski, Dan
    Li, Ju
    Kent, Jeffrey D.
    Pollack, Paul F.
    [J]. GASTROENTEROLOGY, 2007, 132 (01) : 52 - 65
  • [5] COLOMBEL JF, 2008, GUT, V57, pA1
  • [6] Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial
    D'Haens, Geert
    Baert, Filip
    van Assche, Gert
    Caenepeel, Philip
    Vergauwe, Philippe
    Tuynman, Hans
    De Vos, Martine
    van Deventer, Sander
    Stitt, Larry
    Donner, Allan
    Vermeire, Severine
    Van De Mierop, Frank J.
    Coche, Jean-Charles R.
    van der Woude, Janneke
    Ochsenkuehn, Thomas
    van Bodegraven, Ad A.
    van Hootegem, Philippe P.
    Lambrecht, Guy L.
    Mana, Fazia
    Rutgeerts, Paul
    Feagan, Brian G.
    Hommes, Daniel
    [J]. LANCET, 2008, 371 (9613) : 660 - 667
  • [7] Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial
    Farrell, RJ
    Alsahli, M
    Jeen, YT
    Falchuk, KR
    Peppercorn, MA
    Michetti, P
    [J]. GASTROENTEROLOGY, 2003, 124 (04) : 917 - 924
  • [8] Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
    Hanauer, SB
    Feagan, BG
    Lichtenstein, GR
    Mayer, LF
    Schreiber, S
    Colombel, JF
    Rachmilewitz, D
    Wolf, DC
    Olson, A
    Bao, WH
    Rutgeerts, P
    [J]. LANCET, 2002, 359 (9317) : 1541 - 1549
  • [9] Incidence and Importance of Antibody Responses to Infliximab After Maintenance or Episodic Treatment in Crohn's Disease
    Hanauer, Stephen B.
    Wagner, Carrie L.
    Bala, Mohan
    Mayer, Lloyd
    Travers, Suzanne
    Diamond, Robert H.
    Olson, Allan
    Bao, Warren
    Rutgeerts, Paul
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (07) : 542 - 553
  • [10] Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
    Maser, Elana A.
    Villela, Renata
    Silverberg, Mark S.
    Greenberg, Gordon R.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (10) : 1248 - 1254
12